Hong Kong News
Nonpartisan, Noncommercial, unconstrained.
Thursday, Apr 25, 2024
Real, Diverse, Unbiased.
All set for Covid nose vaccine
A nasal-spray Covid-19 vaccine developed by the University of Hong Kong in collaboration with Xiamen University and Beijing-based Wantai BioPharm has been given the green light by mainland authorities.
Wantai BioPharm said the nasal vaccine had gained approval from the Chinese National Medical Products Administration.
The pharmaceutical company said it aims to make 200 million doses of the vaccine in the coming six months.
But the nasal vaccine is subject to approval by Hong Kong before being used in the SAR, HKU said.
A government pandemic adviser, Yuen Kwok-yung, who took part in the research, said it can induce protection at virus entry sites, meaning it may stop the virus from entering the nasal and throat.
"It does not require injections," Yuen said. "Intramuscular injection vaccines can induce systemic immunity, including neutralizing antibodies and T lymphocyte response in the blood but not at the nasal and throat mucosa."
Another HKU microbiology professor, Chen Honglin, said the HKU vaccine is an excellent complement to vaccines that require injectio.
"The nasal vaccine is particularly acceptable to persons who are afraid of needles, such as children. All we need is a syringe with a special tip to produce a mist and does not require an inhalation device," Chen said.
He added that the priority group for taking this vaccine may include the elderly and other high-risk people with underlying illnesses.
HKU said the vaccine has undergone phase one, two and three clinical trials in the mainland, Hong Kong and overseas, including South Africa, Vietnam, Philippines and Columbia.
"The vaccine is found to be safe in all three phases of the clinical trials. In the phase three clinical trial, the vaccine is shown to have over 80 percent protective efficacy against Omicron variant in the population previously vaccinated by inactivated vaccine and 55 percent effective in the unvaccinated population," it said.
Yuen said the HKU research team is continuing to update the nasal vaccine for new Covid variants, including the recent Omicron variant with high transmission.
But the current vaccine developed with the original Covid strain can still protect people from Omicron, he added.
The HKU research on the nasal vaccine received HK$20 million from the SAR government under the Health and Medical Research Fund scheme and another US$5.89 million (HK$45 million) from the Coalition for Epidemic Preparedness Innovations.
Wantai BioPharm said the nasal vaccine was given the go-ahead for clinical trials by the National Medical Products Administration in August 2020.
The first and second phase of clinical trials was conducted in the mainland and Hong Kong, while the third phase was in South Africa, the Philippines, Colombia and Vietnam.
The company said that the vaccine is effective against the Omicron variant and can also protect those who are aged above 60.
The pharmaceutical company said it aims to make 200 million doses of the vaccine in the coming six months.
But the nasal vaccine is subject to approval by Hong Kong before being used in the SAR, HKU said.
A government pandemic adviser, Yuen Kwok-yung, who took part in the research, said it can induce protection at virus entry sites, meaning it may stop the virus from entering the nasal and throat.
"It does not require injections," Yuen said. "Intramuscular injection vaccines can induce systemic immunity, including neutralizing antibodies and T lymphocyte response in the blood but not at the nasal and throat mucosa."
Another HKU microbiology professor, Chen Honglin, said the HKU vaccine is an excellent complement to vaccines that require injectio.
"The nasal vaccine is particularly acceptable to persons who are afraid of needles, such as children. All we need is a syringe with a special tip to produce a mist and does not require an inhalation device," Chen said.
He added that the priority group for taking this vaccine may include the elderly and other high-risk people with underlying illnesses.
HKU said the vaccine has undergone phase one, two and three clinical trials in the mainland, Hong Kong and overseas, including South Africa, Vietnam, Philippines and Columbia.
"The vaccine is found to be safe in all three phases of the clinical trials. In the phase three clinical trial, the vaccine is shown to have over 80 percent protective efficacy against Omicron variant in the population previously vaccinated by inactivated vaccine and 55 percent effective in the unvaccinated population," it said.
Yuen said the HKU research team is continuing to update the nasal vaccine for new Covid variants, including the recent Omicron variant with high transmission.
But the current vaccine developed with the original Covid strain can still protect people from Omicron, he added.
The HKU research on the nasal vaccine received HK$20 million from the SAR government under the Health and Medical Research Fund scheme and another US$5.89 million (HK$45 million) from the Coalition for Epidemic Preparedness Innovations.
Wantai BioPharm said the nasal vaccine was given the go-ahead for clinical trials by the National Medical Products Administration in August 2020.
The first and second phase of clinical trials was conducted in the mainland and Hong Kong, while the third phase was in South Africa, the Philippines, Colombia and Vietnam.
The company said that the vaccine is effective against the Omicron variant and can also protect those who are aged above 60.
